Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Ewing, S. Eirefelt, S. Edsbäcker, A. Miller-Larsson (Lund, Sweden). Relationship between the inhaled and pulmonary absorbed dose of budesonide and mometasone furoate: A study in the isolated perfused rat lung. Eur Respir J 2010; 36: Suppl. 54, 4549

Member's Comments

No comment yet.

Related content which might interest you: Once-daily versus twice-daily administration of mometasone furoate dry powder inhaler (MF-DPI) improves lung function in children with asthma previously maintained on inhaled corticosteroids (ICS) Source: Eur Respir J 2004; 24: Suppl. 48, 164s Year: 2004 In vitro metabolism of ciclesonide, beclomethasone dipropionate, budesonide and fluticasone propionate in human precision-cut lung slices Source: Eur Respir J 2005; 26: Suppl. 49, 255s Year: 2005 Comparison of medium dose inhaled beclomethasone dipropionate (BDP) and low dose inhaled BDP plus sustained-release theophylline in the treatment of patients with moderate persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 42s Year: 2002 A superior improvement in lung function in patients with moderate persistent asthma is seen with mometasone furoate 200 μg b.i.d delivered by dry powder inhaler compared with beclomethasone dipropionate 168 μg Source: Eur Respir J 2001; 18: Suppl. 33, 96s Year: 2001 The pharmacokinetics of mometasone furoate administered by dry powder inhaler following single and multiple dosing in patients with mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 96s Year: 2001 Administration of mometasone furoate once daily in the evening is as effective as mometasone furoate administered twice daily in improving lung function in patients with mild to moderate persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003 Variable lipophilicity of budesonide: Comparison with fluticasone propionate, mometasone furoate, and ciclesonide Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003 Efficacy of the novel inhaled corticosteroid, fluticasone furoate (FF)/long-acting beta2-agonist, vilanterol (VI) combination in reducing COPD exacerbations Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012 Budesonide is better retained in airway tissue than fluticasone propionate and mometasone furoate due to the formation of lipophilic, slowly hydrolyzed budesonide esters Source: Eur Respir J 2003; 22: Suppl. 45, 281s Year: 2003 A novel tool for the assessment of pulmonary disposition of dry powder aerosols; the isolated and perfused rat lung exposed to budesonide, formoterol and terbutaline Source: Eur Respir J 2007; 30: Suppl. 51, 352s Year: 2007 Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once daily inhalation as a fixed-dose combination in healthy subjects Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Airway and systemic effects of hydrofluoroalkane formulations of high dose ciclesonide and fluticasone propionate in moderate persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 583s Year: 2004 Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma Source: Eur Respir J 2014; 43: 773-782 Year: 2014 Once-daily, evening administration of mometasone furoate dry powder inhaler improves pulmonary function in patients with mild to moderate persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 282s Year: 2003 The absolute bioavailability of fluticasone furoate (FF) and vilanterol (VI) trifenatate following inhaled administration in combination in healthy subjects Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011 Lung function effects and safety of fluticasone furoate (FF)/vilanterol (VI) in patients with COPD: Low-mid dose assessment Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012 Lung bioavailability of beclometasone dipropionate and formoterol fumarate fixed dose combination administered using a pMDI or a novel DPI: NEXThaler® Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012 Comparative clinical study of addition theophylline to low-dose inhaled beclomethasone dipropionate and medium-dose inhaled beclomethasone dipropionate in patients with mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 98s Year: 2001 Assessment of the defined daily dose for mometasone furoate dry powder inhaler in persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003